Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection-Reference-Cited by-同舟云学术

Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection

Published:2017-05-12 Issue:6 Volume:37 Page:735-747
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Martin Michelle T.¹²^ORCID,Deming Paulina³

Affiliation:

1. University of Illinois Hospital & Health Sciences System; Chicago Illinois

2. University of Illinois at Chicago, College of Pharmacy; Chicago Illinois

3. College of Pharmacy; University of New Mexico Health Sciences Center; Albuquerque New Mexico

Publisher

Wiley

Subject

Pharmacology (medical)

Reference46 articles.

1. Toward a more accurate estimate of the prevalence of hepatitis C in the United States;Edlin;Hepatology,2015

2. The burden of hepatitis C in the United States;Kim;Hepatology,2002

3. Global epidemiology and genotype distribution of the hepatitis C virus infection;Gower;J Hepatol,2014

4. Centers for Disease Control and Prevention CDC Statistics and Surveillance 2014. Division of Viral Hepatitis-Statistics and Surveillance 2014 http://www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm

5. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region;Nakano;Liver Int,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

2. Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis;Antimicrobial Agents and Chemotherapy;2019-12

3. Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions;Viruses;2019-02-11

4. High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data;Antiviral Therapy;2019

5. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials;Antimicrobial Agents and Chemotherapy;2018-10